|
業務類別
|
Biotechnology |
|
業務概覽
|
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. |
| 公司地址
| Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004 |
| 電話號碼
| +1 844 511-9056 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.larimartx.com |
| 員工數量
| 71 |
| Mr. Michael Celano |
Chief Financial Officer, Secretary and Principal Accounting Officer |
美元 505.00K |
20/04/2026 |
| Dr. Carole Ben-Maimon, M.D. |
Director, President and Chief Executive Officer |
美元 650.00K |
20/04/2026 |
| Dr. Gopi Shankar, F.A.A.P.,M.B.A.,PhD |
Chief Development Officer |
美元 466.00K |
20/04/2026 |
| Dr. Russell G. Clayton, D.O. |
Chief Medical Officer |
-- |
20/04/2026 |
|
|
| Mr. Frank E. Thomas |
Independent Director |
20/04/2026 |
| Mr. Jonathan S. Leff |
Independent Director |
20/04/2026 |
| Mr. Joseph Truitt |
Chairman of the Board |
20/04/2026 |
| Dr. Carole Ben-Maimon, M.D. |
Director, President and Chief Executive Officer |
20/04/2026 |
| Mr. Thomas Edward Hamilton |
Independent Director |
20/04/2026 |
| Dr. Jeffrey W. Sherman, F.A.C.P.,M.D. |
Independent Director |
20/04/2026 |
|
|
|
|
